Navidea Biopharmaceuticals Inc (NAVB)

Currency in USD
0.0005
0.0000(0.00%)
Delayed Data·
NAVB Scorecard
Full Analysis
Stock generally trades with high price volatility
Earnings results expected in 6 days
Fair Value
Day's Range
0.00050.0005
52 wk Range
0.00010.1300
Key Statistics
Prev. Close
0.0005
Open
0.0005
Day's Range
0.0005-0.0005
52 wk Range
0.0001-0.13
Volume
1K
Average Volume (3m)
3.77K
1-Year Change
-50%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAVB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Navidea Biopharmaceuticals Inc Company Profile

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi’s sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Compare NAVB to Peers and Sector

Metrics to compare
NAVB
Peers
Sector
Relationship
P/E Ratio
0.0x−3.5x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
0.0x2.3x2.6x
Price / LTM Sales
0.0x10.3x3.3x
Upside (Analyst Target)
0.0%156.6%43.5%
Fair Value Upside
Unlock−0.4%6.3%Unlock

Earnings

Latest Release
Jun 05, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NAVB Income Statement

People Also Watch

25.90
CNC
-1.20%
68.11
PYPL
+0.15%
170.08
JNJ
-0.56%

FAQ

What Stock Exchange Does Navidea Biopharma Trade On?

Navidea Biopharma is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Navidea Biopharma?

The stock symbol for Navidea Biopharma is "NAVB."

What Is the Navidea Biopharma Market Cap?

As of today, Navidea Biopharma market cap is 50.00K.

What Is Navidea Biopharma's Earnings Per Share (TTM)?

The Navidea Biopharma EPS (TTM) is -0.17.

When Is the Next Navidea Biopharma Earnings Date?

Navidea Biopharma will release its next earnings report on 10 Aug 2025.

From a Technical Analysis Perspective, Is NAVB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Navidea Biopharma Stock Split?

Navidea Biopharma has split 1 times.

How Many Employees Does Navidea Biopharma Have?

Navidea Biopharma has 13 employees.

What is the current trading status of Navidea Biopharma (NAVB)?

As of 05 Aug 2025, Navidea Biopharma (NAVB) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 0.13.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.